© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 18, 1513-1519,
September 15, 1993
© 1993 Oxford University Press
Spectrum of Mutation and Frequency of Allelic Deletion of the p53 Gene in Ovarian Cancer
Department of Obstetrics and Gynecology/Division of Gynecologic Oncology, Duke University Medical Center, and the Duke Comprehensive Cancer Center Durham, N.C.
Department of Surgery, Duke University Medical Center, and the Duke Comprehensive Cancer Center Durham, N.C.
Department of Medicine and Immunology, Duke University Medical Center, and the Duke Comprehensive Cancer Center Durham, N.C.
Laboratory of Molecular Carcinogenesis, National Institutes of Health, Research Triangle Park N.C.
Correspondence to: Andrew Berchuck, M.D., Division of Gynecologic Oncology, Box 3079, Duke University Medical Center, Durham, NC 27710
BACKGROUND: The p53 gene encodes a nuclear phosphoprotein present in low levels in normal human cells. The wild-type form of this protein functions to restrain inappropriate cellular proliferation. Approximately one half of human epithelial ovarian cancers have mutations in the p53 gene and overexpress the mutant protein product. Deletion of one allele of the p53 gene also frequently occurs in these cancers.
PURPOSE: We sought to define the spectrum of mutations in the p53 gene in epithelial ovarian cancer with respect to both the specific codons involved and the type of mutations observed. We also examined the frequency of allelic deletion of the p53 gene in cancers containing p53 gene mutations.
METHODS: Tissue samples from the epithelial ovarian cancers of 62 patients were obtained during initial laparotomy. Histologic examination was done to ensure that the experimental samples used in this study contained more than 75% cancer cells. Total RNA was extracted from these samples and separately from matched control noncancerous regions of the surgical specimen or white blood cells. The purified RNAs were reverse transcribed to generate cDNA copies of exons 4–10 of the p53 gene. Two rounds of polymerase chain reaction (PCR) were conducted to produce enough template for DNA sequence analysis of the regions of interest within the p53 gene. Dideoxy sequencing of at least two independent productions of each amplified DNA template was done to confirm the validity of the mutations found. Allelic deletions were identified by PCR and gel electrophoretic techniques to examine three polymorphisms within the p53 gene in cancer-normal DNA pairs.
RESULTS: We identified 45 mutations in exons 5–8 of the p53 gene, where mutations frequently have been found in other cancer types. An additional mutation was identified in exon 4. Overall, 72% of the mutations were transitions, 24% trans versions, and 4% microdeletions. Allelic deletion of the other p53 allele was seen in 67% of ovarian cancers in which a p53 mutation was present. Germ-line p53 mutations were not found in any patients whose cancers had p53 mutations.
CONCLUSIONS AND IMPLICATIONS: Like p53 mutations in other types of human cancers, those in epithelial ovarian cancers are diverse and occur frequently in exons 5–8. The predominance of transition mutations suggests that p53 mutations in ovarian cancer arise because of spontaneous errors in DNA synthesis and repair rather than the direct interaction of carcinogens with DNA. These molecular data are consistent with data from epidemiologic studies that have failed to demonstrate a convincing relationship between exposure to environmental carcinogens and the development of ovarian cancer. [J Natl Cancer Inst 85:1513–1519, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas Cancer Res., May 1, 2009; 69(9): 4036 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Choi, J. T. Park, B. Davidson, P. J. Morin, I.-M. Shih, and T.-L. Wang Jagged-1 and Notch3 Juxtacrine Loop Regulates Ovarian Tumor Growth and Adhesion Cancer Res., July 15, 2008; 68(14): 5716 - 5723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bartel, J. Jung, A. Bohnke, E. Gradhand, K. Zeng, C. Thomssen, and S. Hauptmann Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival Clin. Cancer Res., January 1, 2008; 14(1): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Dressman, A. Berchuck, G. Chan, J. Zhai, A. Bild, R. Sayer, J. Cragun, J. Clarke, R. S. Whitaker, L. Li, et al. An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer J. Clin. Oncol., February 10, 2007; 25(5): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Yang, D. G. Rosen, I. Mercado-Uribe, J. A. Colacino, G. B. Mills, R. C. Bast Jr, C. Zhou, and J. Liu Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells Carcinogenesis, January 1, 2007; 28(1): 174 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wehbe, R. Henson, M. Lang, F. Meng, and T. Patel Pifithrin-{alpha} Enhances Chemosensitivity by a p38 Mitogen-Activated Protein Kinase-Dependent Modulation of the Eukaryotic Initiation Factor 4E in Malignant Cholangiocytes J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1153 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.-M. Shih and R. J. Kurman Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis Am. J. Pathol., May 1, 2004; 164(5): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Lancaster, H. K. Dressman, R. S. Whitaker, L. Havrilesky, J. Gray, J. R. Marks, J. R. Nevins, and A. Berchuck Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers Reproductive Sciences, January 1, 2004; 11(1): 51 - 59. [Abstract] [PDF]
|
|
|
|
|
|
A. Reles, W. H. Wen, A. Schmider, C. Gee, I. B. Runnebaum, U. Kilian, L. A. Jones, A. El-Naggar, C. Minguillon, I. Schonborn, et al. Correlation of p53 Mutations with Resistance to Platinum-based Chemotherapy and Shortened Survival in Ovarian Cancer Clin. Cancer Res., October 1, 2001; 7(10): 2984 - 2997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sawasaki, K. Shigemasa, Y. Shiroyama, T. Kusuda, T. Fujii, T. H. Parmley, T. J. O'Brien, and K. Ohama Cyclin E mRNA Overexpression in Epithelial Ovarian Cancers: Inverse Correlation with p53 Protein Accumulation Reproductive Sciences, May 1, 2001; 8(3): 179 - 185. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text]
|
|
|
|
|
|
S. Suzuki, D. H. Moore II, D. G. Ginzinger, T. E. Godfrey, J. Barclay, B. Powell, D. Pinkel, C. Zaloudek, K. Lu, G. Mills, et al. An Approach to Analysis of Large-Scale Correlations between Genome Changes and Clinical Endpoints in Ovarian Cancer Cancer Res., October 1, 2000; 60(19): 5382 - 5385. [Abstract] [Full Text]
|
|
|
|
|
|
G. L. Maxwell, J. I. Risinger, K. A. Hayes, A. A. Alvarez, R. K. Dodge, J. C. Barrett, and A. Berchuck Racial Disparity in the Frequency of PTEN Mutations, but not Microsatellite Instability, in Advanced Endometrial Cancers Clin. Cancer Res., August 1, 2000; 6(8): 2999 - 3005. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. A. Werness, P. Parvatiyar, S. J. Ramus, A. S. Whittemore, K. Garlinghouse-Jones, I. Oakley-Girvan, R. A. DiCioccio, J. Wiest, Y. Tsukada, B. A. J. Ponder, et al. Ovarian Carcinoma In Situ With Germline BRCA1 Mutation and Loss of Heterozygosity at BRCA1 and TP53 J Natl Cancer Inst, July 5, 2000; 92(13): 1088 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shigemasa, H. Tanimoto, G. P. Parham, T. H. Parmley, K. Ohama, and T. J. O'Brien Cyclin D1 Overexpression and p53 Mutation Status in Epithelial Ovarian Cancer Reproductive Sciences, March 1, 1999; 6(2): 102 - 108. [Abstract] [PDF]
|
|
|
|
|
|
E. W. Newcomb, M. Sosnow, R. I. Demopoulos, A. Zeleniuch-Jacquotte, J. Sorich, and J. L. Speyer Expression of the Cell Cycle Inhibitor p27KIP1 Is a New Prognostic Marker Associated with Survival in Epithelial Ovarian Tumors Am. J. Pathol., January 1, 1999; 154(1): 119 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berchuck, A. Elbendary, L. Havrilesky, G. C. Rodriguez, and R. C. Bast Pathogenesis of Ovarian Cancers Reproductive Sciences, July 1, 1994; 1(3): 181 - 190. [Abstract] [PDF]
|
|